Development
Core Scientific, Inc.
CORZ
$12.19
$0.262.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -36.40% | -63.63% | -44.89% | -61.98% | -71.18% |
| Total Other Revenue | 50.65% | 3.18% | -11.62% | -26.30% | -46.59% |
| Total Revenue | 17.05% | -30.55% | -22.60% | -37.33% | -59.82% |
| Cost of Revenue | -39.09% | -48.60% | -40.53% | -27.46% | 5.03% |
| Gross Profit | 183.19% | 156.95% | 190.63% | -54.60% | -133.42% |
| SG&A Expenses | -27.25% | -42.07% | -74.43% | -45.20% | 151.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 104.38% | 110.43% | -99.86% | -100.02% | -100.79% |
| Total Operating Expenses | -36.73% | -47.01% | -70.98% | -48.43% | 5.08% |
| Operating Income | 110.51% | 83.88% | 104.02% | 128.45% | -186.42% |
| Income Before Tax | 57.19% | 90.33% | 98.94% | 99.93% | -692.91% |
| Income Tax Expenses | 101.56% | -98.93% | 100.27% | -99.75% | -230.55% |
| Earnings from Continuing Operations | 55.00% | 90.54% | 98.86% | 99.92% | -818.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.00% | 90.54% | 98.86% | 99.92% | -818.68% |
| EBIT | 110.51% | 83.88% | 104.02% | 128.45% | -186.42% |
| EBITDA | 305.76% | 255.97% | 115.83% | 79.59% | -116.03% |
| EPS Basic | 52.32% | 91.23% | 99.01% | 99.93% | -583.70% |
| Normalized Basic EPS | 22.42% | 87.76% | 103.12% | 122.79% | -188.75% |
| EPS Diluted | 51.81% | 91.06% | 99.01% | 99.34% | -777.43% |
| Normalized Diluted EPS | 22.42% | 87.76% | 103.12% | 122.79% | -222.41% |
| Average Basic Shares Outstanding | -5.62% | 7.99% | 15.64% | 22.28% | 48.56% |
| Average Diluted Shares Outstanding | -5.62% | 7.99% | 15.64% | 22.28% | 7.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |